cobas^® 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• De Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 445(1–2), 2–10 (2013).
   PubMedGoogle Scholar
• Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121(3), 621–632 (2007).
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048–1056 (2010).
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Ronco G, Anttila A et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30( Suppl. 5), F88–F99 (2012).
   PubMed Web of Science ®Google Scholar
• Nanda K, Mccrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132(10), 810–819 (2000).
   PubMed Web of Science ®Google Scholar
• Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285(11), 1500–1505 (2001).
   PubMed Web of Science ®Google Scholar
• Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J. Natl Cancer Inst. Monogr. (31), 89–96 (2003).
   PubMedGoogle Scholar
• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32( Suppl. 1), S16–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, De Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202(12), 1789–1799 (2010).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 370(9590), 890–907 (2007).
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072–1079 (2005).
   PubMedGoogle Scholar
• Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24( Suppl. 3), S3/78–89 (2006).
   Google Scholar
• Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62(3), 147–172 (2012).
   PubMed Web of Science ®Google Scholar
• Moyer VA, Force USPST. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 156(12), 880–891, W312 (2012).
   PubMed Web of Science ®Google Scholar
• Canadian Task Force on Preventive Health C, Pollock S, Dunfield L et al. Recommendations on screening for cervical cancer. CMAJ 185(1), 35–45 (2013).
   PubMedGoogle Scholar
• Murphy J, Kennedy EB, Dunn S et al. Cervical screening: a guideline for clinical practice in Ontario. J. Obstet. Gynaecol. Can. 34(5), 453–458 (2012).
   PubMedGoogle Scholar
• Arbyn M, Anttila A, Jordan J et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann. Oncol. 21(3), 448–458 (2010).
   PubMed Web of Science ®Google Scholar
• Castle PE, De Sanjose S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 30( Suppl. 5), F117–F122 (2012).
   Google Scholar
• Zappacosta R, Caraceni D, Ciccocioppo L et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme. Gynecol. Oncol. 128(3), 427–432 (2013).
   PubMedGoogle Scholar
• Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 118(6–7), 520–528 (2010).
   PubMedGoogle Scholar
• Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 30( Suppl. 5), F100–F106 (2012).
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev. Anti Infect. Ther. 8(10), 1139–1162 (2010).
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124(3), 516–520 (2009).
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol. Oncol. 103(1), 12–17 (2006).
   PubMedGoogle Scholar
• Cuzick J, Bergeron C, Von Knebel Doeberitz M et al. New technologies and procedures for cervical cancer screening. Vaccine 30( Suppl. 5), F107–F116 (2012).
   PubMed Web of Science ®Google Scholar
• Preisler S, Rebolj M, Untermann A et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PLoS ONE 8(3), e59765 (2013).
   Google Scholar
• Gilbert L, Oates E, Ratnam S. Stability of cervical specimens in surepath medium for HPV Testing with Roche cobas (R) 4800. J. Clin. Microbiol. 51(10), 3412–3414 (2013).
   PubMedGoogle Scholar
• Rao A, Young S, Erlich H et al. Development and characterization of the cobas human papillomavirus test. J. Clin. Microbiol. 51(5), 1478–1484 (2013).
   PubMedGoogle Scholar
• Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 47(10), 3344–3347 (2009).
   PubMedGoogle Scholar
• Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12(9), 880–890 (2011).
   PubMed Web of Science ®Google Scholar
• Stoler MH, Wright TC Jr, Sharma A et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol. 135(3), 468–475 (2011).
   PubMed Web of Science ®Google Scholar
• Wright TC, Jr., Stoler MH, Sharma A et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am. J. Clin. Pathol. 136(4), 578–586 (2011).
   PubMed Web of Science ®Google Scholar
• Wright TC, Castle PE, Behrens CM, Huh WK. Risk of ≥CIN3 after 3 years of follow-up of 42,209 screened women: end of study results from ATHENA. SGO LBA1 (2013).
   Google Scholar
• Heideman DA, Hesselink AT, Berkhof J et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J. Clin. Microbiol. 49(11), 3983–3985 (2011).
   PubMed Web of Science ®Google Scholar
• Lloveras B, Gomez S, Alameda F et al. HPV testing by cobas HPV test in a population from Catalonia. PLoS ONE 8(3), e58153 (2013).
   Google Scholar
• Gage JC, Sadorra M, Lamere BJ et al. Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J. Clin. Microbiol. 50(1), 61–65 (2012).
   PubMedGoogle Scholar
• Mateos ML, Chacon De Antonio J, Rodriguez-Dominguez M, Sanz I, Rubio MD. [Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening]. Enferm. Infecc. Microbiol. Clin. 29(6), 411–414 (2011).
   PubMedGoogle Scholar
• Lindemann ML, Dominguez MJ, De Antonio JC et al. Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J. Mol. Diagn. 14(1), 65–70 (2012).
   PubMedGoogle Scholar
• Ki EY, Kim HE, Choi YJ, Park JS, Kang CS, Lee A. Comparison of the Cobas 4800 HPV test and the Seeplex HPV4A ACE with the hybrid capture 2 test. Int. J. Med. Sci. 10(2), 119–123 (2013).
   PubMedGoogle Scholar
• Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J. Clin. Microbiol. 50(1), 25–29 (2012).
   PubMedGoogle Scholar
• Lapierre SG, Sauthier P, Mayrand MH et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J. Clin. Microbiol. 50(4), 1240–1244 (2012).
   PubMedGoogle Scholar
• Martinez SB, Palomares JC, Artura A et al. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J. Virol. Methods 180(1–2), 7–10 (2012).
   PubMedGoogle Scholar
• Park Y, Lee E, Choi J, Jeong S, Kim HS. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J. Clin. Microbiol. 50(7), 2359–2365 (2012).
   PubMed Web of Science ®Google Scholar
• Szarewski A, Mesher D, Cadman L et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J. Clin. Microbiol. 50(6), 1867–1873 (2012).
   PubMedGoogle Scholar
• Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 108(4), 908–913 (2013).
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst. 102(19), 1478–1488 (2010).
   PubMedGoogle Scholar
• Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl Cancer Inst. 97(14), 1066–1071 (2005).
   PubMedGoogle Scholar
• Cox JT, Castle PE, Behrens CM et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am. J Obstet. Gynecol. 208(3), 184 e181–184 e111 (2013).
   Google Scholar
• Cuzick J, Thomas Cox J, Zhang G et al. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int. J. Cancer 132(4), 959–966 (2013).
   PubMedGoogle Scholar
• Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. Can. J. Public Health 101(3), 220–225 (2010).
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol. Oncol. 119(2), 237–242 (2010).
   PubMedGoogle Scholar
• De Kok IM, Van Rosmalen J, Dillner J et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344, e670 (2012).
   Google Scholar
• Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br. J. Cancer 106(9), 1571–1578 (2012).
   PubMedGoogle Scholar
• Sroczynski G, Schnell-Inderst P, Muhlberger N et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis. Eur. J. Cancer 47(11), 1633–1646 (2011).
   PubMedGoogle Scholar
• Ogilvie GS, Krajden M, Van Niekerk DJ et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Br. J. Cancer 107(12), 1917–1924 (2012).
   PubMedGoogle Scholar
• Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101(23), 1612–1623 (2009).
   PubMedGoogle Scholar
• Franco EL, Cuzick J, Hildesheim A, De Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24( Suppl. 3), S3/171–177 (2006).
   Google Scholar
• A review of human carcinogens. Part B: Biological agents/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. WHO Press, Lyon, France (2009).
   Google Scholar